Brian Edlin, MD

Recent Publications

Flaherty JP, Waitley D, Edlin BR, George D, Arnow P, O'Keefe P, Weinstein RA. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med 1989; 87(suppl 5A):278-82.

Edlin BR, Weinstein RA, Whaling SM, Ou CY, Connolly PJ, Moore JL, Bitran JD. Zidovudine-interferon-alpha combination therapy in patients with advanced HIV-1 infection: biphasic response of p24 antigen and quantitative PCR. J Infect Dis 1992; 165:793-8.

Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326:1514-21.

Edlin BR, St. Clair MH, Pitha-Rowe PM, Whaling SM, King DM, Bitran JD, Weinstein RA. In vitro resistance to zidovudine and alpha-interferon in HIV-1 isolates from patients: correlations with treatment duration and response. Ann Intern Med 1992; 117(6):457-60.

Bennett CL, Chang H, Shlian D, Dawson JA, Edlin BR. Clinical and economic aspects of HIV disease in a California student health service. West J Med 1992; 157:41-3.

Edlin BR, Irwin KL, Ludwig DD, McCoy HV, Serrano Y, Word C, Bowser BP, Faruque S, McCoy CB, Schilling RF, Holmberg SD, Multicenter Crack Cocaine and HIV Infection Study Team. High-risk sex behavior among young street-recruited crack cocaine smokers in three American cities: an interim report. J Psychoactive Drugs 1992 Oct-Dec; 24(4):363-71. (invited)

Weatherby NL, Shultz JM, Chitwood DD, McCoy HV, McCoy CB, Ludwig DD, Edlin BR. Crack cocaine use and sexual activity in Miami, Florida. J Psychoactive Drugs 1992 Oct-Dec; 24(4):373-80. (invited)

Bastian L, Bennett CL, Adams J, Waskin H, Divine G, Edlin BR. Differences between men and women with HIV-related Pneumocystis carinii pneumonia: experience from 3,070 cases in New York City in 1987. J Acquir Immune Defic Syndr 1993; 6:617-23.

Fitzgibbon JE, Gaur S, Frenkel LD, Laraque F, Edlin BR, Dubin DT. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation. N Engl J Med 1993; 329:1835-41.

Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, Inciardi JA, Bowser BP, Schilling RF, Holmberg SD, Multicenter Crack Cocaine and HIV Infection Study Team. Intersecting epidemics: crack cocaine use and HIV infection among inner-city young adults. N Engl J Med 1994; 331(21):1422-7.

Irwin KL, Edlin BR, Wong L, Faruque S, McCoy HV, Word C, Schilling RF, McCoy CB, Evans PE, Holmberg SD, Multicenter Crack Cocaine and HIV Infection Study Team. Urban rape survivors: characteristics and prevalence of human immunodeficiency virus and other sexually transmitted infections. Obstet Gynecol 1995; 85:330-6.

Stroud LA, Tokars JI, Grieco MH, Crawford JT, Culver DH, Edlin BR, Sordillo EM, Woodley CL, Gilligan ME, Schneider N, Williams J, Jarvis WR. Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. Infect Control Hosp Epidemiol 1995; 16:141-7.

Faruque S, Edlin BR, McCoy CB, Word CO, Larsen SA, Schmid DS, Von Bargen JC, Serrano Y. Oral lesions among crack smokers in three inner-city neighborhoods. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13(1):87-92.

Irwin KL, Edlin BR, Faruque S, McCoy HV, Word C, Serrano Y, Inciardi JA, Bowser BP, Holmberg SD, Multicenter Crack Cocaine and HIV Infection Study Team. Crack cocaine smokers who turn to drug injection: characteristics, factors associated with injection, and implications for HIV transmission. Drug Alcohol Depend 1996; 42:85-92.

El-Bassel N, Schilling RF, Irwin KL, Faruque S, Gilbert L, Chu KT, Serrano Y, Edlin BR. Sex work and psychological distress among women recruited from the streets of Harlem. Am J Public Health 1997; 87(1):66-70.

Curtis JR, Ullman M, Collier AC, Krone RM, Edlin BR, Bennett CL. Variations in medical care for HIV-related Pneumocystis carinii pneumonia: a comparison of process and outcome at two hospitals. Chest 1997; 112:398-405.

Soifer NE, Borzak S, Edlin BR, Weinstein RA. Prevention of peripheral venous catheter complications with an intravenous therapy team )) a randomized, controlled trial. Arch Intern Med 1998; 158:473-7.

Jones DL, Irwin KL, Inciardi J, Bowser B, Schilling R, Word C, Evans P, Faruque S, McCoy V, Edlin BR. The high-risk sexual practices of crack-smoking sex workers recruited from the streets of three American cities. Sex Transm Dis 1998; 25:187-93.

Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Use of an illegal syringe exchange and injection-related risk behaviors among street-recruited injection drug users in Oakland, California, 1992-1995. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:505-11.

Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Drug paraphernalia laws and injection-related infectious disease risk among drug injectors. J Drug Issues 1999; 29:1-16.

Kral AH, Bluthenthal RN, Erringer EA, Lorvick J, Edlin BR. Risk factors among IDUs who give injections to or receive injections from other drug users. Addiction 1999; 94(5):675-83.

Meng Y-X, Spira TJ, Bhat GJ, Birch CJ, Druce JD, Edlin BR, Edwards R, Gunthel C, Newton R, Stamey FR, Wood C, Pellett PE. Individuals from North America, Australasia, and Africa are infected with four different genotypes of human herpesvirus 8. Virology 1999; 261(1):106-119.

Metsch LR, McCoy HV, McCoy CB, Miles CC, Edlin BR, Pereyra M. Use of health care services by women who use crack cocaine. Women Health 1999; 30(1):35-51.

Lorvick J, Thompson S, Edlin BR, Kral AH, Lifson AR, Watters JK. Incentives and accessibility: a pilot study to promote adherence to tuberculosis prophylaxis in a high-risk community. J Urban Health 1999; 76:461-67.

Seal KH, Ochoa K, Hahn JA, Tulsky JP, Edlin BR, Moss, AR. Risk of hepatitis B infection among young injection drug users in San Francisco: opportunities for intervention. West J Med 2000; 172:16-20.

Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. Abscesses and cellulitis among injection drug users in San Francisco. Clin Infect Dis 2000; 30:579-81.

Bluthenthal RN, Kral AH, Gee L, Erringer EA, Edlin BR. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 2000; 14:605-11.

Kral AH, Lorvick J, Edlin BR. Sex and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr 2000; 24:162-7.

El-Bassel N, Schilling RF, Gilbert L, Faruque S, Irwin KL, Edlin BR. Sex trading and psychological distress in a street-based sample of low-income urban men. J Psychoactive Drugs 2000 Jul-Sep; 32(3):259-267.

Lorvick J, Kral AH, Seal KH, Gee L, Edlin BR. Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health 2001; 91(1):46-7.

Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001; 357:1397-401.

Murphy EL, DeVita D, Liu H, Vittinghoff E, Leung P, Ciccarone DH, Edlin BR. Risk factors for skin and soft tissue abscess among injection drug users: a case-control study. Clin Infect Dis 2001; 33:35-40.

Burris S, Norland J, Edlin BR. Legal aspects of providing naloxone to heroin users in the United States. Int J Drug Policy 2001; 12:237-48.

Seal KH, Kral AH, Gee L, Moore LD, Bluthenthal RN, Lorvick J, Edlin BR. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. Am J Public Health 2001; 91:1842-6.

Bluthenthal RN, Kral AH, Gee L, Lorvick J, Moore LD, Seal KH, Edlin BR. Trends in HIV seroprevalence and risk among gay and bisexual men who inject drugs in San Francisco, 1988 to 2000. J Acquir Immune Defic Syndr 2001; 28:264-9.

Cannon MJ, Dollard SC, Black JP, Edlin BR, Hannah C, Hogan SE, Patel MM, Jaffe HW, Offermann MK, Spira TJ, Pellett PE, Gunthel CJ. Risk factors for Kaposi's sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 2003; 17:215-22.

Kral AH, Lorvick J, Gee L, Bacchetti P, Rawal B, Busch M, Edlin BR. Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998. Am J Epidemiol 2003;157:915-22.

Atkinson J, Edlin BR, Engels EA, Seal KH, Kral AH, Whitby D, O’Brien TR. Seroprevalence of human herpesvirus 8 among injection drug users in San Francisco. J Infect Dis 2003;187:974-81.

Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR. Fatal heroin-related overdose in San Francisco, 1997–2000: a case for targeted intervention. J Urban Health 2003; 80:261-73.

Seal KH, Downing M, Kral AH, Singleton-Banks S, Hammond JP, Lorvick J, Ciccarone D, Edlin BR. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay area. J Urban Health 2003; 80:291-301.

Snead J, Downing M, Lorvick J, Garcia B, Thawley R, Kegeles S, Edlin BR. Secondary syringe exchange among injection drug users. J Urban Health 2003; 80:330-48.

Pfeiffer R, Tanaka Y, Yeo AE, Umemura T, Seal KH, Shih JW, Alter HJ, Edlin BR, O'Brien TR. Prevalence of SEN viruses among injection drug users in the San Francisco Bay area. J Infect Dis 2003;188:13-8.

Seal KH, Kral AH, Lorvick J, McNees A, Gee L, Edlin BR. A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 2003;71:127-31.

Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR, Delwart EL. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J Virol 2004;78:94-103.

Tanaka Y, Pfeiffer R, Yeo AE, Mizokami M, Edlin BR, Castle P, O’Brien TR, Alter HJ, Shih JW-K. PCR-probe capture hybridization assay and statistical model for SEN virus prevalence estimation. J Med Virol 2004;73(1):123-30.

Canchis PW, Gonzalez SA, Fiel MI, Chiriboga L, Yee H, Edlin BR, Jacobson IM, Talal AH. Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum alpha-fetoprotein. Liver 2004;24:198-203.

Charlebois ED, Perdreau-Remington F, Kreiswirth B, Bangsberg DR, Ciccarone D, Ng VL, Chansky K, Edlin BR, Chambers HF. Origins of community strains of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2004;39:47-54.

Canchis PW, Yee HT, Fiel MI, Davila J, Dieterich DT, Liu R-C, Chiriboga L, Jacobson IM, Edlin BR, Talal AH. Intrahepatic CD4+ cell depletion and apoptosis in hepatitis C virus/HIV–coinfected patients. J Acquir Immune Defic Syndr 2004;37:1125–31.

Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004:39:1540-3.

Downing M, Riess TH, Vernon K, Mulia N, Hollinquest M, McKnight C, Des Jarlais DC, Edlin BR. It takes a community: successful implementation of syringe exchange programs. AIDS Educ Prev 2005; 17(1):68-78.

Kral AH, Lorvick J, Ciccarone D, Wenger L, Gee L, Martinez A, Edlin BR. HIV prevalence and risk behaviors among men who have sex with men and inject drugs in San Francisco. J Urban Health 2005;82(1 Suppl 1):i43-i50.

Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, Downing M, Edlin BR. Providing naloxone and resuscitation training to injection drug users to prevent heroin overdose death. J Urban Health 2005;82(2):303-11.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR. A randomized trial of pegylated interferon alfa-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100(11):2453-62.

Gonzalez SA, Liu RC, Edlin BR, Jacobson IM, Talal AH. Human immunodeficiency-virus hepatitis C virus-coinfected patients with normal alanine aminotransferase levels. J Acquir Immune Defic Syndr 2006;41(5):582-9.

Bourgois P, Martinez A, Kral A, Edlin BR, Schonberg J, Ciccarone D. Reinterpreting ethnic patterns among white and African American men who inject heroin: A social science of medicine approach. PLoS Med 2006; 3(10): (e452)1805-15. doi: 10.1371/journal.pmed.0030452.

Tseng FC, O’Brien TR, Zhang M, Kral A, Ortiz-Conde BA, Busch MP, Edlin BR. Seroprevalence of hepatitis B and C viruses among San Francisco Bay area injection drug users, 1998-2000. Hepatology 2007:46(3):666-71.

Bluthenthal RN, Do DP, Finch BK, Martinez A, Edlin BR, Kral AH. Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: A multi-level analysis. J Urban Health 2007;84(5):653-66.

Bacchetti P, Tien PC, Seaberg EC, O’Brien TR, Augenbraun MH, Kral AH, Busch MP, Edlin BR. Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression. BMC Infect Dis 2007; 7:145.

Page-Shafer K, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR, Moss AR, Wright TL, Wright DJ, O'Brien TR, Caglioti S, Busch MP. Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and project HCV incidence rates. J Clin Microbiol. In press.

Mizukoshi E, Eisenbach C, Edlin BR, Newton KP, Raghuraman S, Weiler-Normann C, Tobler LH, Busch MP, Carrington M, McKeating JA, O’Brien TR, Rehermann B. Hepatitis C virus-specific immune responses of frequently exposed long-term injection drug users. Under review.

Ahmed F, Edlin BR, Petrovic L, Jacobson IM. The impact of diabetes on chronic hepatitis C infection: diabetes is associated with fibrosis progression in CHC patients independent of steatosis. Under review.

Tseng FC, Zhang M, Kral A, Busch MP, Ortiz-Conde BA, Welzel TM, Edlin BR, O’Brien TR. The association between chronic HBV infection and chronic HCV infection among injection drug users varies with years of injection drug use. Under review.

Miguelino V, Kral AH, Bruckner T, Lorvick J, Dietrich RM, Edlin BR. Working towards a behavioral measure of harm reduction: the Individualized Harm Reduction Commitment. Under review.

Brown EE, Zhang M, Zarin-Pass R, Bernig T, Tseng FC, Yeager M, Edlin BR, Chanock SJ, O’Brien TR. MBL2 and clearance of hepatitis C virus among injection drug users. Under review.

Weiss JJ, Bhatti L, Dieterich DT, Edlin BR, Fishbein DA, Goetz MB, Yu K, Wagner GJ. Hepatitis C patients’ self-reported adherence to pegylated interferon and ribavirin. Under review.